不同分数抑菌浓度解读标准评估抗真菌药物体外联合效应比较

摘要/Abstract

摘要：

目的明确酮康唑联合特比萘芬或萘替芬相互作用模式,评估不同分数抑菌浓度解读标准对判断抗真菌药物体外联合效应的影响。方法参考CLSI微量液基稀释法M27-A3和M38-A2方案,采用棋盘微量稀释法对100株分离自临床真菌病患者的菌株进行酮康唑与特比萘芬或奈替芬体外联合药敏试验,包括皮肤癣菌,念珠菌和马拉色菌。采用不同分数抑菌浓度解读标准评估酮康唑与特比萘芬或奈替芬体外联合效应,A标准定义为:FICI≤0.5为协同作用,0.54为拮抗作用;B标准:FICI≤0.5为协同作用,0.52为拮抗作用;C标准:FICI<1为协同作用,FICI=1为相加作用,12为拮抗作用。结果 A标准与B标准具有较好的一致性,C标准则较为宽松。根据C标准进行解读会明显扩大协同效应范围。结论定义FICI≤0.5为协同作用,0.54为拮抗作用的解读标准,具有简便、一致性好的优点,值得临床采用。

关键词: 抗真菌药物, 联合, 药敏实验, 分数抑菌浓度

Abstract:

Objective To determine the interaction pattern of ketoconazole combined with terbinafine or naftifine, and to evaluate the effects of different interpretation criterions of fractional inhibitory concentration index (FICI) for the in vitro combined effect of antifungal drugs.Methods According to CLSI M38-A2 and M27-A3, a checkerboard broth microdilution method was performed to investigate the in vitro activities of ketoconazole in combination with terbinafine or naftifine against 100 clinical strains isolated from patients with mycosis, including dermatophyte, Candida and Malassezia.Different criterion for the interpretation of fractional inhibitory concentration were employed to evaluate the in vitro combined effect of ketoconazole in combination with terbinafine or naftifine.Standard A:synergy is defined by FICI ≤0.5, antagonism by FICI>4, and no interaction by FICI>0.5, but ≤4;Standard B:synergy is defined by FICI ≤0.5, additive by FICI>0.5, but ≤1, no interaction by FICI>1, but ≤2, and antagonism by FICI>2;Standard C:synergy is defined by FICI ≤1, additive by FICI=1, no interaction by FICI>1, but ≤2, and antagonism by FICI>2.Results Standard A had good consistency with Standard B, Standard C is relatively lenient.According to Standard C, the interpretation might significantly expand the range of synergy.Conclusions The interpretation criterion of fractional inhibitory concentration (Synergy is defined by FICI ≤0.5, antagonism by FICI>4, and no interaction by FICI>0.5, but ≤4) has the advantage of simplicity, convenience and good consistence, and it is worthy of clinical application.

Key words: antifungal agents, combination, susceptibility testing, fractional inhibitory concentration

中图分类号:

R978.5

吴伟伟, 王千, 龚杰, 万喆, 王爱平, 李若瑜. 不同分数抑菌浓度解读标准评估抗真菌药物体外联合效应比较[J]. 中国真菌学杂志, 2016, 11(2): 85-89.

WU Wei-wei, WANG Qian, GONG Jie, WAN Zhe, WANG Ai-ping, LI Ruo-yu. Comparision of different interpretation criterions of fractional inhibitory concentration for evaluating the in vitro combined effect of antifungal agents[J]. Chinese Journal of Mycology, 2016, 11(2): 85-89.

参考文献

[1] Hosokawa K,Yamazaki H,Mochizuki K,et al.Successful treatment of Trichosporon fungemia in a patient with refractory acute myeloid leukemia using voriconazole combined with liposomal amphotericin B[J].Transpl Infect Dis,2012,14(2):184-187.
[2] Ogawa T,Takezawa K,Tojima I,et al.Successful treatment of rhino-orbital mucormycosis by a new combination therapy with liposomal amphotericin B and micafungin[J].Auris Nasus Larynx,2012,39(2):224-228.
[3] Zhang J,Xi L,Lu C,et al.Successful treatment for chromoblastomycosis caused by Fonsecaea monophora:a report of three cases in Guangdong,China[J].Mycoses,2009,52(2):176-181.
[4] Bhat SV,Paterson DL,Rinaldi MG,et al.Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease:successful combination therapy with voriconazole and terbinafine[J].Scand J Infect Dis,2007,39(1):87-90.
[5] Berenbaum MC.A method for testing for synergy with any number of agents[J].J Infect Dis,1978,137(2):122-130.
[6] Li Y,Wan Z,Li R.In vitro activities of nine antifungal drugs and their combinations against Phialophora verrucosa[J].Antimicrob Agents Chemother,2014,58(9):5609-5612.
[7] Tamura T,Asahara M,Yamamoto M,et al.In vitro susceptibility of dermatomycoses agents to six antifungal drugs and evaluation by fractional inhibitory concentration index of combined effects of amorolfine and itraconazole in dermatophytes[J].Microbiol Immunol,2014,58(1):1-8.
[8] Nguyen MH,Barchiesi F,McGough DA,et al.In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var.neoformans[J].Antimicrob Agents Chemother,1995,39(8):1691-1695.
[9] Clinical and Laboratory Standards Institute.Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi;Approved Standard,2nd ed.CLSI document M38-A2[S].Clinical and Laboratory Standards Institute,Wayne,PA,2008.
[10] Clinical and Laboratory Standards Institute.Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts;Approved Standard,3rd ed.CLSI document M27-A3[S].Clinical and Laboratory Standards Institute,Wayne,PA,2008.
[11] Leeming JP,Notman FH.Improved methods for isolation and enumeration of Malassezia furfur from human skin[J].J Clin Microbiol,1987,25(10):2017-2019.
[12] Miranda KC,de Araujo CR,Costa CR,et al.Antifungal activities of azole agents against the Malassezia species[J].Int J Antimicrob Agents,2007,29(3):281-284.
[13] Evans EG.Resistance of Candida species to antifungal agents used in the treatment of onychomycosis:a review of current problems[J].Br J Dermatol,1999,141(Suppl 56):33-35.
[14] Czaika V,Tietz HJ,Schmalreck A,et al.Antifungal susceptibility testing in chronically recurrent vaginal candidosis as basis for effective therapy[J].Mycoses,2000,43(Suppl 2):45-50.
[15] Gupta AK,Kohli Y.In vitro susceptibility testing of ciclopirox,terbinafine,ketoconazole and itraconazole against dermatophytes and nondermatophytes,and in vitro evaluation of combination antifungal activity[J].Br J Dermatol,2003,149(2):296-305.
[16] Cuenca-Estrella M.Combinations of antifungal agents in therapy——what value are they?[J].J Antimicrob Chemother,2004,54(5):854-869.
[17] Yu J,Li R,Zhang M,et al.In vitro interaction of terbinafine with itraconazole and amphotericin B against fungi causing chromoblastomycosis in China[J].Med Mycol,2008,46(7):745-747.
[18] Zhang X,Huang H,Feng P,et al.In vitro activity of itraconazole in combination with terbinafine against clinical strains of itraconazole-insensitive Sporothrix schenckii[J].Eur J Dermatol,2011,21(4):573-576.
[19] Scheid LA,Mario DA,Kubica TF,et al.In vitro activities of antifungal agents alone and in combination against fluconazole-susceptible and-resistant strains of Candida dubliniensis[J].Braz J Infect Dis,2012,16(1):78-81.
[20] Ahmed SA,Kloezen W,Fahal AH,et al.In vitro interaction of currently used azoles with terbinafine against Madurella mycetomatis[J].Antimicrob Agents Chemother,2015,59(2):1373-1374.
[21] Odds FC.Synergy,antagonism,and what the chequerboard puts between them[J].J Antimicrob Chemother,2003,52(1):1.